市場調查報告書

局部性腎小球硬化(FSGS):市場洞察,流行病學,到2028年前的市場預測

Focal Segmental Glomerulosclerosis (FSGS) - Market Insight, Epidemiology and Market Forecast -2030

出版商 DelveInsight Business Research LLP 商品編碼 905935
出版日期 內容資訊 英文 187 Pages
商品交期: 最快1-2個工作天內
價格
局部性腎小球硬化(FSGS):市場洞察,流行病學,到2028年前的市場預測 Focal Segmental Glomerulosclerosis (FSGS) - Market Insight, Epidemiology and Market Forecast -2030
出版日期: 2020年04月01日內容資訊: 英文 187 Pages
簡介

本報告提供全球局部性腎小球硬化(FSGS)市場的相關調查,提供市場/疾病概要,流行病學,潛在的需求,競爭的主要產品,美國·德國·法國·義大利·西班牙·英國·日本的市場分析等資訊。

目錄

第1章 重要的洞察

第2章 局部性腎小球硬化(FSGS):市場概要

  • 2017年:市場佔有率(%)分佈
  • 2028年:市場佔有率(%)分佈

第3章 疾病概要:局部性腎小球硬化

  • 簡介
  • FSGS的分類
  • 徵兆及症狀
  • 組織病理學
  • 病因
  • 病因
  • 生物標記
  • FSGS的診斷
    • 鑑別診斷

第4章 流行病學及患者人口

  • 主要調查結果
  • 主要7個國家的整體患者數局部分節性腎小球硬化症
  • 國家智慧 - 局部分節性腎小球硬化症的流行病學
  • 美國
    • 假設及根據
    • 一般的病例
    • 性別病例
    • 各類型病例
    • 各年齡病例
  • 歐洲5個國家
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第5章 目前治療方法

  • 腎臟疾病:全球改善的成果 - KDIGO指南 - 成人的特發性FSGS

第6章 潛在的需求

第7章 主要競爭

  • Sparsentan: Retrophin
    • 藥的說明
    • 其他開發活動
    • 臨床開發
    • 安全性及有效性
    • 產品簡介
  • DMX-200: Dimerix
  • Voclosporin: Aurinia Pharmaceuticals
  • CXA-10: Complexa
  • Abatacept: Bristol-Myers Squibb
    • 產品說明
    • 其他開發活動
  • Bardoxolone methyl: Reata Pharmaceuticals/協和麒麟株式會社
  • Bleselumab: Astellas Pharma/協和麒麟株式會社
  • CCX140: Chemocentryx
  • PF-06730512: Pfizer

第8章 局部性腎小球硬化:7個主要的市場分析

  • 主要調查結果
  • 主要7個國家的局部性腎小球硬化的市場規模
  • 各國市場預測
  • 美國:市場預測
  • 美國的市場規模
    • 整體市場規模
    • 第1選擇療法:各市場規模
    • 第2選擇療法:各市場規模
  • 歐洲5個國家:市場預測
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第9章 市場成長要素

第10章 市場障礙

第11章 附錄

第12章 報告方法

第13章 DelveInsight的服務內容

第14章 免責聲明

第15章 關於DelveInsight

第16章 免責聲明

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0669

DelveInsight's 'Focal Segmental Glomerulosclerosis (FSGS) - Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the Focal Segmental Glomerulosclerosis (FSGS), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Focal Segmental Glomerulosclerosis (FSGS) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted FSGS symptoms market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Focal Segmental Glomerulosclerosis (FSGS) symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Focal Segmental Glomerulosclerosis (FSGS) Disease Understanding and Treatment Algorithm

Focal Segmental Glomerulosclerosis (FSGS) Overview

Focal segmental glomerulosclerosis (FSGS) is a well-defined histologic pattern of injury characterized by sclerosis, hyalinosis, foam-cell infiltration, vacuolization of podocytes, and podocyte precursor proliferation between glomeruli tuft and Bowman's capsule.The use of the word "focal" signifies that in FSGS, only some glomeruli are sclerosed, and "segmental" means that only a portion of the affected glomerulus is affected. It typically presents with nephrotic syndrome with characterized proteinuria and, obliteration or failure of glomerular capillary loops by increased extracellular matrix in glomeruli capillary tufts.

FSGS is one of the most common causes of primary glomerular disease in children and adults, which may progress to end-stage renal disease (ESRD) with a relatively high risk. Commonly, it is divided into primary (idiopathic) and secondary FSGS. Primary FSGS sometimes has no identifiable cause or known etiology, and it is linked to genetic mutations in podocyte-specific proteins, whereas, secondary FSGS may occur in response to previous glomerular injury, glomerular hypertension, hypertrophy, drug toxicity, some malignancies or viral infections, obesity, and reduced renal mass. The clinical features of FSGS are the features of nephrotic syndrome and include peripheral edema, marked proteinuria, hypertension, hypoalbuminemia, hyperlipidemia, and progressive loss of renal function.

FSGS is further classified as collapsing, tip, cellular, perihilar, and not otherwise specified variants according to the location and character of the sclerotic lesion. Also, primary or idiopathic FSGS is considered to be related to podocyte injury, and the pathogenesis of podocyte injury has been actively investigated. Disease presentation and associated medical conditions are beneficial to distinguish between primary and secondary FSGS. Conditions, such as infections, hypertension, and obesity, as well as proteinuria that is within nephrotic range but not accompanied by the full-blown nephrotic syndrome are suggestive of secondary FSGS.

Focal segmental glomerulosclerosis (FSGS) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Focal segmental glomerulosclerosis (FSGS) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight Focal segmental glomerulosclerosis (FSGS) market report gives a thorough understanding of FSGS symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides FSGS symptoms of treatment algorithms and treatment guidelines for FSGS symptoms in the US, Europe, and Japan.

Focal segmental glomerulosclerosis (FSGS) Epidemiology

The FSGS symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted FSGS epidemiology segmented as the Total prevalence of FSGS, Gender-Specific cases of FSGS, and Clinical Subtype specific cases of FSGS. The report includes the prevalent scenario of FSGS symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Focal segmental glomerulosclerosis (FSGS) Epidemiology

The epidemiology segment also provides the Focal segmental glomerulosclerosis (FSGS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total prevalent population of FSGS in 7MM countries was estimated to be 202,687 in 2017.

Focal segmental glomerulosclerosis (FSGS) Drug Chapters

The drug chapter segment of the Focal segmental glomerulosclerosis (FSGS) report encloses the detailed analysis of FSGS marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Focal segmental glomerulosclerosis (FSGS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Currently, there are no FDA-approved therapies for FSGS. The therapeutic market size of FSGS in the US is mainly accounted for the off-label treatment options, such as non-immune therapy in conjunction with immunotherapy.

Products detail in the report…

Focal segmental glomerulosclerosis (FSGS) Emerging Drugs

Sparsentan: Retrophin

Sparsentan is a novel investigational, dual mechanism of action that acts as potent angiotensin receptor blocker (ARB) and strongly selective endothelin receptor (ETA) antagonist, with in vitro selectivity toward endothelin receptor type A. It has also received orphan drug designation for FSGS from both FDA and EMA. Currently, it is in the phase III development for the FSGS.

Products detail in the report…

Focal segmental glomerulosclerosis (FSGS) Market Outlook

The Focal segmental glomerulosclerosis (FSGS) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Focal segmental glomerulosclerosis (FSGS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Focal segmental glomerulosclerosis (FSGS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Focal segmental glomerulosclerosis (FSGS) market in 7MM is expected to change in the study period 2017-2030.

The current therapeutic landscape in the 7MM is divided into conventional therapies such as angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, corticosteroids, calcineurin inhibitors (CNI) which are considered as first-line therapy for steroid-resistant nephrotic syndrome and in patients with relapsing disease, mycophenolate mofetil a third-line agent, is often used in combination with other immunosuppressants and has milder adverse reactions than CNIs, and Rituximab which are also considered as the first line of therapy followed by transplant.

Key Findings

This section includes a glimpse of the Focal segmental glomerulosclerosis (FSGS) market in 7MM. The market size of FSGS in the seven major markets was found to be USD 286.40 million in 2017.

The United States Market Outlook

This section provides the total Focal segmental glomerulosclerosis (FSGS) market size and market size by therapies in the United States.

The United States accounts for the highest market size of FSGS in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. FSGS in the US is mainly accounted for the off-label treatment options, such as non-immune therapy in conjunction with immunotherapy. The non-immune therapy includes the control of blood pressure, lipids, and weight by using angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARB) while the immunotherapy includes, corticosteroids (Prednisone), calcineurin inhibitors (Cyclosporine and Tacrolimus), Mycophenolate Mofetil, and Biologics (Rituximab), as well as Plasma exchange for those seriously ill patients. Moreover, in case of medication failure, dialysis and kidney transplant become the next treatment options. Despite these available treatments, the management of FSGS remains a challenge due to the complex causes of disease and dense pathogenesis.

EU-5 Countries: Market Outlook

The total Focal segmental glomerulosclerosis (FSGS) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

There is a lack of approved therapy for the treatment of Focal segmental glomerulosclerosis (FSGS), management of FSGS depends on the use of off label medications in Europe. Regardless of all available treatments, there is unsatisfied patients' outcome under the current treatments, therefore, innovation are encouraged on the treatment strategy based on Kidney Disease, Improving Global Outcomes guideline, and international collaborations are required for the potential novel immunosuppressive or immunomodulatory therapies.

Japan Market Outlook

The total Focal segmental glomerulosclerosis (FSGS) market size and market size by therapies in Japan are also mentioned.

Focal segmental glomerulosclerosis (FSGS) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers Focal segmental glomerulosclerosis (FSGS) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Focal segmental glomerulosclerosis (FSGS) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Focal segmental glomerulosclerosis (FSGS) key players involved in developing targeted therapeutics.

Major players include Retrophin, Dimerix, Aurinia Pharmaceuticals, Complexa, Bristol-Myers Squibb, Reata Pharmaceuticals/ Kyowa Kirin, Astellas Pharma/Kyowa Kirin, Pfizer, Chemocentryx, ZyVersa Therapeutics and others. Currently, Sparsentan (Retrophin) designation will give an advantage in both the US and EU markets and is expected to get launch in 2022

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for Focal segmental glomerulosclerosis (FSGS) emerging therapies.

Reimbursement Scenario in FSGS

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business & price strategy.

According to USRDS statistics, costs of dialysis provided by Medical Centers have been estimated to exceed those in private settings, in part because patients had more comorbidities, outpatient and emergency visits, prescriptions, and longer hospital stays.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Focal segmental glomerulosclerosis (FSGS) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Focal segmental glomerulosclerosis (FSGS) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive & Market Intelligence analysis of the Focal segmental glomerulosclerosis (FSGS) Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of FSGS, explaining its causes, signs and symptoms, pathophysiology and currently available therapies
  • Comprehensive insight has been provided into the Focal segmental glomerulosclerosis (FSGS) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Focal segmental glomerulosclerosis (FSGS) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Focal segmental glomerulosclerosis (FSGS) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Focal segmental glomerulosclerosis (FSGS) market

Report Highlights:

  • In the coming years, Focal segmental glomerulosclerosis (FSGS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Focal segmental glomerulosclerosis (FSGS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for FSGS. Launch of emerging therapies will significantly impact the Focal segmental glomerulosclerosis (FSGS) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for FSGS
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Focal segmental glomerulosclerosis (FSGS) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Focal segmental glomerulosclerosis (FSGS) Pipeline Analysis
  • Focal segmental glomerulosclerosis (FSGS) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Focal segmental glomerulosclerosis (FSGS) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Focal segmental glomerulosclerosis (FSGS) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Focal segmental glomerulosclerosis (FSGS) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What were the Focal segmental glomerulosclerosis (FSGS) Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Focal segmental glomerulosclerosis (FSGS) total market Size as well as market Size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Focal segmental glomerulosclerosis (FSGS)market Size during the forecast period (2017-2030)?
  • At what CAGR, the Focal segmental glomerulosclerosis (FSGS) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Focal segmental glomerulosclerosis (FSGS) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Focal segmental glomerulosclerosis (FSGS) market growth till 2030 and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the FSGS?
  • What is the historical Focal segmental glomerulosclerosis (FSGS) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What would be the forecasted patient pool of Focal segmental glomerulosclerosis (FSGS) in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to FSGS?
  • Out of all 7MM countries, which country would have the highest prevalent population of Focal segmental glomerulosclerosis (FSGS) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Focal segmental glomerulosclerosis (FSGS) along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Focal segmental glomerulosclerosis (FSGS) in the USA, Europe, and Japan?
  • What are the Focal segmental glomerulosclerosis (FSGS) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of FSGS?
  • How many therapies are developed by each company for the treatment of FSGS?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of FSGS?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Focal segmental glomerulosclerosis (FSGS) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Focal segmental glomerulosclerosis (FSGS) and their status?
  • What are the key designations that have been granted for the emerging therapies for FSGS?
  • What are the global historical and forecasted market of FSGS?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Focal segmental glomerulosclerosis (FSGS) market
  • To understand the future market competition in the Focal segmental glomerulosclerosis (FSGS) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Focal segmental glomerulosclerosis (FSGS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Focal segmental glomerulosclerosis (FSGS) market
  • To understand the future market competition in the Focal segmental glomerulosclerosis (FSGS) market

Table of Contents

1 Key Insights

2 Executive summary

3 Key Organizations

4 Epidemiology and Market Methodology

5 Focal Segmental Glomerulosclerosis (FSGS): Market Overview at a Glance

  • 5.1 Market Share (%) Distribution of FSGS in 2017
  • 5.2 Market Share (%) Distribution of FSGS in 2030

6 Disease Overview: Focal Segmental Glomerulosclerosis

  • 6.1 Introduction
  • 6.2 Classification of FSGS
  • 6.3 Signs and Symptoms
  • 6.4 Histopathology
  • 6.5 Etiology
  • 6.6 Pathogenesis
  • 6.7 Biomarkers
  • 6.8 Diagnosis of FSGS
    • 6.8.1 Differential Diagnosis

7 Epidemiology and Patient Population

  • 7.1 Key Findings
  • 7.2 7MM Total Prevalent Population of Focal Segmental Glomerulosclerosis
  • 7.3 Country Wise-Epidemiology of Focal Segmental Glomerulosclerosis
  • 7.4 United States
    • 7.4.1 Assumptions and Rationale
    • 7.4.2 Prevalent Cases of Focal Segmental Glomerulosclerosis in the United States
    • 7.4.3 Gender-specific Cases of Focal Segmental Glomerulosclerosis in the US
    • 7.4.4 Type-specific Cases of Focal Segmental Glomerulosclerosis in the US
  • 7.5 EU5
    • 7.5.1 Assumptions and Rationale
  • 7.6 Germany
    • 7.6.1 Prevalent Cases of Focal Segmental Glomerulosclerosis in Germany
    • 7.6.2 Gender-specific Cases of Focal Segmental Glomerulosclerosis in Germany
    • 7.6.3 Type-specific Cases of Focal Segmental Glomerulosclerosis in Germany
  • 7.7 France
    • 7.7.1 Prevalent Cases of Focal Segmental Glomerulosclerosis in France
    • 7.7.2 Gender-specific Cases of Focal Segmental Glomerulosclerosis in France
    • 7.7.3 Type-specific Cases of Focal Segmental Glomerulosclerosis in France
  • 7.8 Italy
    • 7.8.1 Prevalent Cases of Focal Segmental Glomerulosclerosis in Italy
    • 7.8.2 Gender-specific Cases of Focal Segmental Glomerulosclerosis in Italy
    • 7.8.3 Type-specific Cases of Focal Segmental Glomerulosclerosis in Italy
  • 7.9 Spain
    • 7.9.1 Prevalent Cases of Focal Segmental Glomerulosclerosis in Spain
    • 7.9.2 Gender-specific Cases of Focal Segmental Glomerulosclerosis in Spain
    • 7.9.3 Type-specific Cases of Focal Segmental Glomerulosclerosis in Spain
  • 7.1 United Kingdom
    • 7.10.1 Prevalent Cases of Focal Segmental Glomerulosclerosis in the United Kingdom
    • 7.10.2 Gender-specific Cases of Focal Segmental Glomerulosclerosis in the United Kingdom
    • 7.10.3 Type-specific Cases of Focal Segmental Glomerulosclerosis in the UK
  • 7.11 Japan
    • 7.11.1 Assumptions and Rationale
    • 7.11.2 Prevalent Cases of Focal Segmental Glomerulosclerosis in Japan
    • 7.11.3 Gender-specific Cases of Focal Segmental Glomerulosclerosis in Japan
    • 7.11.4 Type-specific Cases of Focal Segmental Glomerulosclerosis in Japan

8 Current Treatment Practices

  • 8.1 Kidney Disease: Improving Global Outcomes- KDIGO Guideline: Idiopathic FSGS in adults

9 Unmet Needs

10 Emerging Therapies

  • 10.1 Key cross competition
  • 10.1 Sparsentan: Retrophin
    • 10.1.1 Drug Description
    • 10.1.2 Other Developmental Activities
    • 10.1.3 Clinical Development
    • 10.1.4 Safety and Efficacy
    • 10.1.5 Product Profile
  • 10.2 DMX-200: Dimerix
    • 10.2.1 Drug Description
    • 10.2.2 Other Developmental Activities
    • 10.2.3 Clinical Development
    • 10.2.4 Safety and Efficacy
    • 10.2.5 Product Profile
  • 10.3 Voclosporin: Aurinia Pharmaceuticals
    • 10.3.1 Drug Description
    • 10.3.2 Other Developmental Activities
    • 10.3.3 Clinical Development
    • 10.3.4 Safety and Efficacy
    • 10.3.5 Product Profile
  • 10.4 CXA-10: Complexa
    • 10.4.1 Drug Description
    • 10.4.2 Other Developmental Activities
    • 10.4.3 Clinical Development
    • 10.4.4 Safety and Efficacy
    • 10.4.5 Product Profile
  • 10.5 Abatacept: Bristol-Myers Squibb
    • 10.5.1 Product Description
    • 10.5.2 Other Development Activities
    • 10.5.3 Clinical Development
    • 10.5.4 Product Profile
  • 10.6 Bardoxolone methyl: Reata Pharmaceuticals/Kyowa Kirin
    • 10.6.1 Drug Description
    • 10.6.2 Other Development Activities
    • 10.6.3 Clinical Development
    • 10.6.4 Safety and Efficacy
    • 10.6.5 Product Profile
  • 10.7 Bleselumab: Astellas Pharma/Kyowa Kirin
    • 10.7.1 Drug Description
    • 10.7.2 Clinical Development
    • 10.7.3 Product Profile
  • 10.8 CCX140: Chemocentryx
    • 10.8.1 Drug Description
    • 10.8.2 Other Developmental Activities
    • 10.8.3 Clinical Development
    • 10.8.4 Safety and Efficacy
    • 10.8.5 Product Profile
  • 10.9 PF-06730512: Pfizer
    • 10.9.1 Drug Description
    • 10.9.2 Clinical Development
    • 10.9.3 Product Profile
  • 10.1 VAR 200: ZyVersa Therapeutics
    • 10.10.1 Drug Description
    • 10.10.2 Other Developmental Activities
    • 10.10.3 Clinical Development
    • 10.10.4 Safety and Efficacy
    • 10.10.5 Product Profile

11 Focal Segmental Glomerulosclerosis: 7 Major Market Analysis

  • 11.1 Key Findings
  • 11.2 Market Size of Focal Segmental Glomerulosclerosis in 7MM

12 Market Outlook by Country

13 The United States: Market Outlook

  • 13.1 United States Market Size
    • 13.1.1 Total Market Size of Focal Segmental Glomerulosclerosis
    • 13.1.2 Market Size of Focal Segmental Glomerulosclerosis by Therapies
  • 13.2 EU-5 Countries: Market Outlook
  • 13.3 Germany
    • 13.3.1 Total Market Size of Focal Segmental Glomerulosclerosis
    • 13.3.2 Market Size of Focal Segmental Glomerulosclerosis by Therapies
  • 13.4 France
    • 13.4.1 Total Market Size of Focal Segmental Glomerulosclerosis
    • 13.4.2 Market Size of Focal Segmental Glomerulosclerosis by Therapies
  • 13.5 Italy
    • 13.5.1 Total Market Size of Focal Segmental Glomerulosclerosis
    • 13.5.2 Market Size of Focal Segmental Glomerulosclerosis by Therapies
  • 13.6 Spain
    • 13.6.1 Total Market Size of Focal Segmental Glomerulosclerosis
    • 13.6.2 Market Size of Focal Segmental Glomerulosclerosis by Therapies
  • 13.7 United Kingdom
    • 13.7.1 Total Market Size of Focal Segmental Glomerulosclerosis
    • 13.7.2 Market Size of Focal Segmental Glomerulosclerosis by Therapies

14 Japan: Market Outlook

    • 14.1.1 Total Market Size of Focal Segmental Glomerulosclerosis
    • 14.1.2 Market Size of Focal Segmental Glomerulosclerosis by Therapies

15 Access and Reimbursement policies

  • 21.1. Overview for Current and Future Therapies:
  • 15.1 Future Therapies:

16 Market Drivers

17 Market Barriers

18 Case Studies

  • 18.1 A Case Report of Focal Segmental Glomerulosclerosis (FSGS) in a patient with Mantle Cell Lymphoma (MCL) - Rare presentation
  • 18.2 A Successfully Treated Case of Recurrent FSGS with Plasmapheresis and High dose Methylprednisolone Pulse Therapy

19 SWOT Analysis

20 KOL Views

21 Appendix

Report Methodology

22 DelveInsight Capabilities

23 Disclaimer

24 About DelveInsight

25 Disclaimer

List of Tables

  • Table 1: List of organization
  • Table 3: Characteristic clinical and pathology features of the six forms of FSGS
  • Table 4: Causes of focal segmental glomerulosclerosis
  • Table 5: Genes related to FSGS or nephrotic syndrome
  • Table 6: Diagnostic protein biomarker candidates for FSGS
  • Table 7: Prognostic candidate biomarkers
  • Table 8: Differential diagnoses of FSGS
  • Table 9: Prevalent Population of Focal Segmental Glomerulosclerosis in 7MM (2017-2030)
  • Table 10: Prevalent Cases of FSGS in the United States (2017-2030)
  • Table 11: Gender-specific cases of FSGS in the United States (2017-2030)
  • Table 12: Type-specific Cases of FSGS in the United States (2017-2030)
  • Table 13: Prevalent Cases of FSGS in Germany (2017-2030)
  • Table 14: Gender-specific cases of FSGS in Germany (2017-2030)
  • Table 15: Type-specific Cases of FSGS in Germany (2017-2030)
  • Table 16: Prevalent Cases of FSGS in France (2017-2030)
  • Table 17: Gender-specific cases of FSGS in France (2017-2030)
  • Table 18: Type-specific Cases of FSGS in France (2017-2030)
  • Table 19: Prevalent Cases of FSGS in Italy (2017-2030)
  • Table 20: Gender-specific cases of FSGS in Italy (2017-2030)
  • Table 21:Type-specific Cases of FSGS in Italy (2017-2030)
  • Table 22: Prevalent Cases of FSGS in Spain (2017-2030)
  • Table 23: Gender-specific cases of FSGS in Spain (2017-2030)
  • Table 24: Type-specific Cases of FSGS in Spain (2017-2030)
  • Table 25: Prevalent Cases of FSGS in the United Kingdom (2017-2030)
  • Table 26: Gender-specific cases of FSGS in the United Kingdom (2017-2030)
  • Table 27: Type-specific Cases of FSGS in the UK (2017-2030)
  • Table 28: Prevalent Cases of FSGS in Japan (2017-2030)
  • Table 29: Gender-specific cases of FSGS in Japan (2017-2030)
  • Table 30: Type-specific Cases of FSGS in Japan (2017-2030)
  • Table 31: Pharmacologic therapies for FSGS
  • Table 32: KDIGO Definitions in Adult FSGS
  • Table 33: KDIGO Guideline: Idiopathic FSGS in adults
  • Table 34: Emerging Drugs Analysis-Key cross comparison
  • Table 35: Sparsentan, Clinical Trial Description, 2020
  • Table 36: DMX-200, Clinical Trial Description, 2020
  • Table 37: Voclosporin Clinical Trial Description, 2020
  • Table 38: CXA-10, Clinical Trial Description, 2020
  • Table 39: Abatacept, Clinical Trial Description, 2020
  • Table 40: Bardoxolone methyl, Clinical Trial Description, 2020
  • Table 41: Bleselumab, Clinical Trial Description, 2020
  • Table 42: CCX140-B, Clinical Trial Description, 2020
  • Table 43: PF-06730512, Clinical Trial Description, 2020
  • Table 44: 7 Major Market Size of Focal Segmental Glomerulosclerosis in USD Million (2017-2030)
  • Table 45: United States Market Size of FSGS, in USD Million (2017-2030)
  • Table 46: Market Size of FSGS by Therapies in USD Million (2017-2030)
  • Table 47: Germany Market Size of FSGS, in USD Million (2017-2030)
  • Table 48: Market Size of FSGS by Therapies in USD Million (2017-2030)
  • Table 49: France Market Size of FSGS, in USD Million (2017-2030)
  • Table 50: Market Size of FSGS by Therapies in USD Million (2017-2030)
  • Table 51: Italy, Market Size of FSGS, in USD Million (2017-2030)
  • Table 52: Market Size of FSGS by Therapies in USD Million (2017-2030)
  • Table 53: Spain, Market Size of FSGS, in USD Million (2017-2030)
  • Table 54: Market Size of FSGS by Therapies in USD Million (2017-2030)
  • Table 55: UK Market Size of FSGS, in USD Million (2017-2030)
  • Table 56: Market Size of FSGS by Therapies in USD Million (2017-2030)
  • Table 57: Japan, Market Size of FSGS, in USD Million (2017-2030)
  • Table 58:Market Size of FSGS by Therapies in USD Million (2017-2030)

List of Figures

  • Figure 1: Epidemiology and Market Methodology
  • Figure 2: Focal Segmental Glomerulosclerosis
  • Figure 3: Common symptoms of FSGS
  • Figure 4: Histopathology of minimal change disease and focal segmental glomerulosclerosis
  • Figure 5: Pathogenesis of FSGS
  • Figure 6: Prevalent Population of Focal Segmental Glomerulosclerosis in 7MM (2017-2030)
  • Figure 7: Prevalent Cases of FSGS in the United States (2017-2030)
  • Figure 8: Gender-specific Prevalent Cases of FSGS in the US (2017-2030)
  • Figure 9: Type-specific Diagnosed Prevalent Cases of FSGS in the US (2017-2030)
  • Figure 10: Prevalent Cases of FSGS in Germany (2017-2030)
  • Figure 11: Gender-specific of FSGS in Germany (2017-2030)
  • Figure 12: Type-specific Cases of FSGS in Germany (2017-2030)
  • Figure 13: Prevalent Cases of FSGS in France (2017-2030)
  • Figure 14: Gender-specific Cases of FSGS in France (2017-2030)
  • Figure 15: Type-specific Cases of FSGS in France (2017-2030)
  • Figure 16: Prevalent Cases of FSGS in Italy (2017-2030)
  • Figure 17: Gender-specific Cases of FSGS in Italy (2017-2030)
  • Figure 18: Type-specific Cases of FSGS in Italy (2017-2030)
  • Figure 19: Prevalent Cases of FSGS in Spain (2017-2030)
  • Figure 20: Gender-specific Cases of FSGS in Spain (2017-2030)
  • Figure 21: Type-specific Cases of FSGS in Spain (2017-2030)
  • Figure 22: Prevalent Cases of FSGS in the United Kingdom (2017-2030)
  • Figure 23: Gender-specific Cases of FSGS in the United Kingdom (2017-2030)
  • Figure 24: Type-specific Cases of FSGS in the UK (2017-2030)
  • Figure 25: Prevalent Cases of FSGS in Japan (2017-2030)
  • Figure 26: Gender-specific Cases of FSGS in Japan (2017-2030)
  • Figure 27: Type-specific Cases of FSGS in Japan (2017-2030)
  • Figure 28: A Treatment algorithm of FSGS
  • Figure 29: Unmet Needs
  • Figure 30: Seven Major Market Size of Focal Segmental Glomerulosclerosis in USD Million (2017-2030)
  • Figure 31: Market Size of FSGS in the United States, USD Millions (2017-2030)
  • Figure 32: Market Size of FSGS by Therapies in USD Million (2017-2030)
  • Figure 33: Market Size of FSGS in Germany, USD Millions (2017-2030)
  • Figure 34: Market Size of FSGS by Therapies in USD Million (2017-2030)
  • Figure 35: Market Size of FSGS in France, USD Millions (2017-2030)
  • Figure 36: Market Size of FSGS by Therapies in USD Million (2017-2030)
  • Figure 37: Market Size of FSGS in Italy, USD Millions (2017-2030)
  • Figure 38: Market Size of FSGS by Therapies in USD Million (2017-2030)
  • Figure 39: Market Size of FSGS in Spain, USD Millions (2017-2030)
  • Figure 40: Market Size of FSGS by Therapies in USD Million (2017-2030)
  • Figure 41: Market Size of FSGS in the UK, USD Millions (2017-2030)
  • Figure 42: Market Size of FSGS by Therapies in USD Million (2017-2030)
  • Figure 43: Market Size of FSGS in Japan, USD Millions (2017-2030)
  • Figure 44:Market Size of FSGS by Therapies in USD Million (2017-2030)
  • Figure 45:Market Drivers
  • Figure 46:Market Barriers